Skip to main content

Table 3 Subgroup analyses of studies on the sentinel lymph node identification

From: The combination of blue dye and radioisotope versus radioisotope alone during sentinel lymph node biopsy for breast cancer: a systematic review

Subgroups No. of studies OR 95 % CI P value Heterogeneity (I2)
Clinical node status
 Negative 14 2.56 1.88–3.49 <0.05 48.7
 Positive 1 1.42 0.68–2.96 >0.05
 Mixed 4 1.93 0.99–3.76 >0.05 59.5
NAC
 Before NAC 6 2.96 1.78–4.94 <0.05 15.6
 After NAC 3 1.53 0.94–2.47 >0.05 31.6
Proportion of patients with positive LSG
 ≥ 90 % 7 1.41 0.83–2.39 >0.05 22.1
 < 90 % 6 2.99 1.99–4.48 <0.05 42.8
Data source
 RCT 6 2.25 1.23–4.11 <0.05 74.7 %
 NPS 18 1.96 1.40–2.74 <0.05 62.5 %
Sample size
 > 300 15 2.01 1.42–2.84 <0.05 75.9 %
 < 300 9 2.01 1.28–3.15 <0.05 7.0 %
Location
 USA 8 1.33 0.82–2.16 >0.05 80.1 %
 Europe 11 2.48 1.60–3.84 <0.05 43.7 %
 Asia 5 2.93 2.05–4.19 <0.05 1.3 %
Injection site of blue dye
 Superficial 10 1.95 0.93–4.08 >0.05 70.6 %
 Deep 9 2.76 2.32–3.30 <0.05 0
Injection site of radioisotope
 Superficial 9 2.05 0.87–4.84 >0.05 76.0 %
 Deep 11 2.55 1.93–3.37 <0.05 31.2 %
  1. LSG lymphoscintigraphy, NAC neoadjuvant chemotherapy
\